Investigational Drug Information for Lexaptepid Pegol
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Lexaptepid Pegol?
Lexaptepid Pegol is an investigational drug.
There have been 4 clinical trials for Lexaptepid Pegol.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Anemia, Chronic Disease, and Kidney Failure, Chronic. The leading clinical trial sponsors are NOXXON Pharma AG and [disabled in preview].
Summary for Lexaptepid Pegol
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 53 |
WIPO Patent Applications | 54 |
Japanese Patent Applications | 6 |
Clinical Trial Progress | Phase 2 (2012-09-01) |
Vendors | 1 |
Recent Clinical Trials for Lexaptepid Pegol
Title | Sponsor | Phase |
---|---|---|
Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients | NOXXON Pharma AG | Phase 1/Phase 2 |
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer | NOXXON Pharma AG | Phase 2 |
Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model | NOXXON Pharma AG | Phase 1 |
Clinical Trial Summary for Lexaptepid Pegol
Top disease conditions for Lexaptepid Pegol
Top clinical trial sponsors for Lexaptepid Pegol
US Patents for Lexaptepid Pegol
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |